A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

ClinicalTrials.gov ID: NCT07219043

Public ClinicalTrials.gov record NCT07219043. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 20, 2026, 11:44 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Placebo-Controlled, Multicenter, Randomized Phase 2 Trial Evaluating the Efficacy and Safety of Felzartamab in Recipients of Kidney Transplants With Late Isolated Microvascular Inflammation (MVI)

Study identification

NCT ID: NCT07219043
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Biogen; Industry
Enrollment: 81 participants

Conditions and interventions

Conditions

Microvascular Inflammation

Interventions

Felzartamab Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 74 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 4, 2026
Primary completion: Feb 9, 2028
Completion: Feb 9, 2028
Last update posted: May 17, 2026

2026 – 2028

United States locations

U.S. sites: 15
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
Keck Hispital of University of Southern California (USC)	Los Angeles	California	90033	Recruiting
Cedars-Sinai Medical Center	Los Angeles	California	90048	Recruiting
Providence St. Joseph Hospital Orange	Orange	California	92868	Recruiting
Sutter Health - California Pacific Medical Center	San Francisco	California	94115	Recruiting
University of California San Fransisco (UCSF) Medical Center	San Francisco	California	94158	Recruiting
Mayo Clinic Rochester	Rochester	Minnesota	55905	Recruiting
Washington University School of Medicine	St Louis	Missouri	63110	Recruiting
University of Nebraska Medical Center	Omaha	Nebraska	68198	Recruiting
Cooperman Barnabas Medical Center	West Orange	New Jersey	07039	Recruiting
Duke University Hospital	Durham	North Carolina	27710	Recruiting
Cleveland Clinic	Cleveland	Ohio	44195	Recruiting
The Ohio State University	Columbus	Ohio	43210	Recruiting
University of Texas Southwestern Medical Center	Dallas	Texas	75390	Recruiting
University of Washington Medical Center	Seattle	Washington	98195	Recruiting
Medical College of Wisconsin	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07219043, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 17, 2026 · Synced May 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07219043 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →